Scientists at Inventisbio Co. Ltd. and Inventisbio LLC have synthesized phosphatidylinositol 3-kinase α (PI3Kα) inhibitors reported to be useful for the treatment of cancer, PIK3CA-related overgrowth spectrum (PROS) and congenital lipomatous overgrowth, vascular malformations, epidermal naevi and skeletal abnormalities (CLOVES syndrome).
Arvinas Operations Inc. has disclosed proteolysis targeting chimera (PROTAC) compounds consisting of a cereblon E3 ubiquitin ligase binding moiety coupled to a Raf kinase B G466V and/or V600E mutant targeting agent through a linker.
Caris Discovery, the therapeutic research arm of Caris Life Sciences Inc., has established a multiyear strategic partnership with Merck KGaA to accelerate the discovery and development of first-in-class antibody-drug conjugates for cancer patients.
Aethon Therapeutics Inc. has entered into a collaboration agreement with Revolution Medicines Inc. under which Aethon will use its Hapimmune platform to discover novel bispecific antibodies to mount an immune attack directed towards cancer cells hit by Revolution Medicines’ RAS(ON) inhibitors.
Bladder cancer is among the top 10 malignant tumors, still with a high mortality rate. There is a need for reliable biomarkers for early diagnosis of the disease. Proximity extension analysis (PEA) is a method that uses a quantitative PCR readout to analyze protein levels in plasma in longitudinal studies and genomic association studies.
Bridge Medicines LLC has divulged protein ENL (MLLT1; YEATS1) and/or FLT3 (FLK2/STK1) inhibitors potentially useful for the treatment of acute lymphocytic leukemia and acute myeloid leukemia.
Ono Pharmaceutical Co Ltd. has identified diacylglycerol kinase α (DGK-α, DGKA) and/or diacylglycerol kinase ζ (DGK-ζ, DGKZ) inhibitors reported to be useful for the treatment of cancer.
It has been previously demonstrated that while cancer cells with defects in ataxia telangiectasia mutated kinase (ATM) signaling are susceptible to ataxia telangiectasia and Rad3-related (ATR) inhibition following treatment with DNA-damaging drugs, normal cells can tolerate ATR inhibition by activating an ATM-mediated compensatory DNA damage response.
Conformation-X Therapeutics LLC has closed an oversubscribed funding tranche of $3.65 million to support the company’s development of a pipeline of immunotherapies that activate both the innate and adaptive arms of the immune system.
RSS
